Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bio-Rad Laboratories Inc Signs Definitive Agreement to Acquire AbD Serotec from MorphoSys AG
Bio-Rad Laboratories Inc announced that it has signed a definitive agreement to acquire AbD Serotec, a division of MorphoSys AG for EUR53 million in cash. The transaction is subject to certain closing conditions and is expected to be completed in January.
Latest Developments for Bio-Rad Laboratories Inc
- Bio-Rad Laboratories Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
- Bio-Rad Laboratories Inc Issues FY 2013 Revenue Guidance Above Analysts' Estimates-Conference Call
- Bio-Rad Laboratories Inc Lowers FY 2012 Revenue Guidance-Conference Call
- Bio-Rad Laboratories Inc Sees FY 2012 Revenue Guidance At Bottom End Of Prior Range-Conference Call
Latest Key Developments in Medical
- Share this
- Link this
- Digg this
Follow Reuters